Squires Again Broadens Discretion for Post-Grant Proceedings
March 13, 2026, 8:14 AM
By: Aziz Burgy, Jerome P. David
On Wednesday, March 11, 2026, United States Patent and Trademark Office (USPTO) Director John Squires issued a memorandum[1] announcing that when making institution decisions in inter partes review (IPR) and post-grant review (PGR) proceedings, he would consider whether accused or licensed products and components were manufactured in the United States, as well as whether the petitioner was a small business that had been sued for infringement. The Director’s stated concern is perceived threats to America’s innovation leadership caused by substantial movement of the country’s manufacturing base overseas. Squires noted that much of this movement happened when IPR and PGR proceedings had a broad institution framework, and that many of the most frequent filers of such proceedings are large companies that conducted most of their manufacturing offshore.
The Director’s reasoning in this memorandum appears to be in line with his previous policies on institution decisions and concerns about foreign threats. In October 2025, he issued a memorandum requiring disclosure of real parties in interest in IPR petitions, based partially on concerns that the IPR process had been exploited by foreign state-backed actors.
This latest memorandum is an extensive and novel expansion of what the Director will consider under his discretion in an institution decision. While IPR and PGR proceedings assess the patentability of a patent claim, this new focus on the manufacturing location of products and related components incorporates elements related to commercialization into the institution decision. Ultimately, the memorandum offers new institution arguments for small and/or domestic petitioners, while implicitly limiting the IPR and PGR prospects of foreign manufacturers.
[1] The memorandum applies to all IPRs and PGRs where the due date for a patent owner discretionary brief has not yet elapsed.

To subscribe to our publications, click here.
News & Insights
News & Insights
Informa 35th Annual Advanced EU London Conference
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
IPWatchdog Sixth Annual Live Conference
Speaking Engagement
Intellectual Property
ABA White Collar Crime Institute 2026
Speaking Engagement
Back to the Well: FDA’s Draft Guidance on New Clinical Investigation Exclusivity
Axinn Viewpoints
Intellectual Property
Mother, May I? The Use of Prior Approval Requirements in Merger Settlements
Podcast
Antitrust
The Curtain Rises Again on FTC Act Section 5
Axinn Viewpoints
Jeny Maier Named Finalist for Managing Partner of the Year in 2026 Women, Influence & Power in Law Awards
Awards & Recognitions
DOJ Serves Up a Statement of Interest with a Side of Fries
Axinn Viewpoints
Antitrust
GCR Live Cartels: 2026
Speaking Engagement
Antitrust
